News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
A securities class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) on behalf of investors who suffered losses between February 15
NovaRed Mining (NREDF) has identified two large copper-gold anomalies ten kilometers from Hudbay's (HBM) producing Copper Mountain mine, arguing this discovery is significant for national security given the West's reliance on foreign copper. While NovaRed is a high-risk exploration company with no reserves or …
Copper prices have surged nearly 50% in the last 12 months, signaling an economic boom, a phenomenon often referred to as "Doctor Copper." This rise is primarily driven by massive capital spending in AI infrastructure, particularly data centers, which are highly copper-intensive. Recent economic …
Freeport-McMoRan (NYSE:FCX) is under renewed scrutiny as gold prices stabilize amidst ongoing Iran-US peace talks. As a significant producer of both copper and gold, the company's performance and market sentiment are heavily influenced by developments in the metals sector and broader geopolitical events. This …
Damora Therapeutics, Inc. announced that it granted equity awards to six new non-executive employees on August 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of options to purchase 451,000 ordinary shares with a 10-year term and an exercise price of …
Perceptive Advisors LLC has acquired a significant stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA), purchasing over 5.1 million shares valued at approximately $9.95 million. This investment represents about 2.75% of the company, contributing to the 47.65% institutional ownership of Neumora Therapeutics. While analyst sentiment is …
This article summarizes recent analyst ratings for three healthcare companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY), and Fortrea Holdings Inc. (FTRE). Needham maintained a Buy rating for Bicycle Therapeutics, William Blair maintained a Buy for Alnylam Pharma, and Bank of America Securities maintained a …
Freeport-McMoRan (FCX) reported strong Q2 results and projects significantly higher copper and gold sales for the second half of 2026 and into 2027, driven by volume growth. This upgraded sales outlook reinforces the company's volume-driven investment thesis, with copper sales expected to increase over …
Freeport-McMoRan, Inc. (NYSE:FCX) generated $25.91 billion USD in revenue last year, with its Indonesia Operations segment contributing the most at $8.62 billion USD. Geographically, the United States was the largest contributor, accounting for $9.03 billion USD. The article provides a breakdown of the company's …
Levi & Korsinsky LLP has announced a class action lawsuit against Neumora Therapeutics, Inc. (NMRA) on behalf of shareholders who suffered losses. The lawsuit alleges that Neumora made false statements and concealed information regarding its Phase Three Program and Phase Two trial data for …
Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $6.57 against a current price of $1.65. While several analysts recently lowered their price targets, the general sentiment remains positive. Institutional investors hold …
Freeport-McMoRan (FCX) recently updated its sales guidance for higher copper and gold volumes through 2027, alongside strong Q2 results. Despite a positive market narrative suggesting the stock is undervalued at $70.68 compared to its current $63.44, another perspective notes its P/E ratio of 31x …
Freeport-McMoRan stock is holding up reasonably well as the stock market corrects. This options trade aims for income from the copper stock. Continue Reading
The Bureau of Land Management (BLM) is seeking public comment on a proposed land exchange with Freeport Minerals Corporation, which is part of Freeport-McMoRan. The swap involves exchanging approximately 5,700 acres of BLM land in Graham, Greenlee, and Cochise counties for 25,000 acres held …
This article reports on a Form 144 SEC filing by Freeport-McMoRan Inc. (FCX) on July 30, 2026. The filing indicates a proposed sale of 7,550 shares of common stock, valued at $475,650.00, by an individual who acquired them through a restricted stock lapse on …
This article compares USA Rare Earth (USAR) and Freeport-McMoRan (FCX) as mining stock investments, concluding that Freeport-McMoRan is the better option despite USA Rare Earth's higher theoretical upside. While USA Rare Earth offers significant potential returns from its "mine-to-magnet" model, it carries higher risks …
Wedbush has increased its price target for Damora Therapeutics (DMRA) to $40 from $35, while reiterating an Outperform rating. The company currently holds an average rating of Buy from analysts, with a mean price target of $44.11.
The article provides an overview of Freeport-McMoRan Inc's (FCX) institutional confidence score, which stands at 7.00, placing it 13th out of 127 in the Metals & Mining industry. The institutional shareholding proportion is 88.87%, a slight decrease quarter-over-quarter. Barrow Hanley is identified as the …
Freeport-McMoRan Inc. (FCX) saw its stock decline by 2.68% on Wednesday, closing at $59.99. This underperformance occurred on a generally negative trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average also falling. This marks the stock's second …
Sharemaestro market context Trend signal active 52 weeks +81.6% · Next-week setup positive 58.6%Freeport-McMoRan headquarters in Phoenix BY JHVEPhoto Freeport-McMoRan Inc. (FCX), headquartered in Phoenix, Arizona, is a leading international metals company with the objective of being foremost in copper. With a market cap of $88.6 billion, the company mines mineral properties exploring copper, gold, molybdenum, silver, …
Neumora Therapeutics (NMRA) is projected to release its Q2 2026 earnings before market open on August 5th, with analysts anticipating a loss of $0.23 per share. The company previously exceeded estimates with a $0.30-per-share loss. Despite recent target price reductions, analysts maintain a "Moderate …
H.C. Wainwright has reiterated its Buy rating for Neumora Therapeutics (NMRA.US) and maintained a target price of $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Strong demand for copper, driven by its use in electric vehicles, AI, and power infrastructure, is boosting its price in 2026 and leading to gains in the ProShares Ultra Copper K-1 Free ETF (UCOP). While UCOP offers double daily exposure to copper futures, amplifying …
Implied volatility for Freeport-McMoRan Inc. (FCX) stock options, particularly the Sept. 18, 2026 $23 Call, is currently surging, indicating expectations of a significant price movement. This high implied volatility suggests either a major upcoming event or a potential trading opportunity for options traders, despite …
Freeport-McMoRan (FCX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this mining company have …
Sharemaestro market context Trend signal active 52 weeks +81.6% · Next-week setup positive 58.6%(RTTNews) - Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company, on Monday released positive pre-clinical toxicology data for NMRA-215, an NLRP3 inhibitor developed for treating obesity and cardiometabolic disease. NMRA-215 is an oral drug candidate that shows high brain penetration and targets the NLRP3 …
Search by ticker symbol or company name and select a result to open its chart.